CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Menu
Begin main content
Home About CADTH What We Do Programs and Services CADTH Common Drug Review Reports semaglutide
Back to Programs and Services

CADTH Common Drug Review

semaglutide

Last Updated: October 24, 2019
Result type: Reports
Project Number: SR0637-000
Product Line: Common Drug Review

Generic Name: semaglutide

Brand Name: TBC

Manufacturer: Novo Nordisk Canada Inc.

Indications: diabetes mellitus, type 2

Manufacturer Requested Reimbursement Criteria1:

For the treatment of adult patients with type 2 diabetes mellitus to improve glycemic control, in combination with metformin (second line treatment) and in combination with metformin and sulfonylurea (third line treatment).

Submission Type: New

Project Status: Pending

Call For Patient Input: October 24, 2019

Patient Input Closed: December 12, 2019

Fee Schedule: Pending

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Related Content